Psychiatr. pro Praxi, 2003; 3: 101-106

Endokrinologie klimakteria a hormonální substituční terapie

prof. MUDr. Jaroslav Živný DrSc, MUDr. Tomáš Fait
Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze

Keywords: climacterium, menopause, endocrinology, hormone replacement therapy.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Živný J, Fait T. Endokrinologie klimakteria a hormonální substituční terapie. Psychiatr. praxi. 2003;4(3):101-106.

Klimakterium je období přechodu mezi reprodukčním obdobím a seniem, ve kterém postupně zaniká funkce vaječníků. V tomto období nastává u žen řada endokrinních, metabolických, organických a psychických změn, které jsou součástí procesu stárnutí a které často negativně ovlivňují kvalitu života. Příčina klimakterických změn a z toho vyplývajících obtíží je s největší pravděpodobností multifaktoriální. Základní příčinou je vyčerpání folikulů v ovariu a v důsledku toho nedostatek ovariálních steroidů, zejména estrogenů. Základem prevence a léčby akutního (vegetativního) a organicko-metabolického klimakterického estrogen deficitního syndromu je hormonální substituční terapie (HST), která spočívá v podávání estrogen-progestogenních preparátů (u žen s dělohou), nebo preparátů obsahujících pouze estrogeny (u žen po hysterektomii).

Endocrinology of Climacterium and Hormone Replacement Therapy

Climacterium is a period of transition from reproductive years to senile years characterized by progressive loss of ovarian function. During this period women undergo number of endocrine, metabolic, somatic and psychological changes which are part of aging and which often negatively affect their quality of life. These changes are most likely multifactorial in origin. The main cause is exhaustion of ovarian follicles which results in lack of ovarian steroids, mainly estrogens. The basis of prevention and therapy of acute/vegetative and organic-metabolic climacteric estrogen deficiency syndrome is hormone replacement therapy (HRT), which includes estrogen-progesterone medications (in women with uterus), or only estrogen medications (in women after hysterectomy).

Download citation

References

  1. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy, The Lancet 2002; 360: 942-944. Go to original source... Go to PubMed...
  2. Cardozo L. Urogynecology, London: Churchil Livingstone, 1997: 729 s.
  3. Cibula D, Henzl MR, Živný J, et al. Základy gynekologické endokrinologie, Grada-Avicenum, Praha 2002: 340 s.
  4. Colditz GA, et al. Menopause and the risk of coronary heart disease in women, N. Engl. J. Med. 316/1987; 1105-1110. Go to original source... Go to PubMed...
  5. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy, The Lancet 1997; 350: 1047-1059. Go to original source... Go to PubMed...
  6. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention, J Am Med Assoc 2002; 288: 366-368. Go to original source... Go to PubMed...
  7. Furberg CD, et al. Subgroup interactions in the heart and estrogenúprogestin replacement study, Circulation 2002; 105: 917-922. Go to original source... Go to PubMed...
  8. Genazzani AR, Gambacciani M. A personal initiative for women´s health: to chalange the Women´s Health Initiative, Gynecol Endocrinol, 2002; 16: 255-257. Go to original source...
  9. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham study. Ann Intern Med 1978; 89: 157-161. Go to original source... Go to PubMed...
  10. Grady D, Herrington D, Bittner V. Heart and estrogen/progestin replacement study follow-up (HERS II). Cardiovascular disease outcomes during 6-8 years of hormone therapy, JAMA 2002; 288: 49-57. Go to original source... Go to PubMed...
  11. Grodstein F, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease, N Engl J Med, 1996; 335: 453-461. Go to original source... Go to PubMed...
  12. Grodstein F, Colditz GA, Stampfer MJ. Post-menopausal hormone use and tooth loss: a prospective study, JADA 1996; 127: 453-461. Go to original source... Go to PubMed...
  13. Hoibraaten E, et al. Increased risk in recurent venous trombolembolism during hormone replacement therapy: results of the randomized, double blind, placebo controlled estrogen in venous trombembolism trial (EVTET), Tromb Haemost 2000; 84: 961-967. Go to original source...
  14. Hulley S, et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart desease in postmenopausal women, JAMA 280, 1998: 605-613. Go to original source... Go to PubMed...
  15. Klein BEK, Klein R, Lee KE. Reproductive exposures, incident age-related cataracts and age-related maculopathy in women: The Beaver Dam Eye Study, Am J Ophthalmol 2000; 130: 322-326. Go to original source... Go to PubMed...
  16. Nanda K, et al. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis, Obstetrics and Gynecology 1999; 93: 880-888. Go to original source...
  17. Paganini-Hill A. ERT and Alzheimer disease, BJOG 1996; 103 (Suppl. 13): 80-86.
  18. Schlipak MG, et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenoapusal women, Circulation 2001; 104: 2300-2304. Go to original source... Go to PubMed...
  19. The Writing Group for the PEPI Trial: Effect of estrogen or estrogen/progestin regimens on heart disease factors in postmenopausal women, JAMA 1995; 273: 199-208. Go to original source... Go to PubMed...
  20. Van de Mooren MJ, et al. HRT may reduce high serum homocystein in postenopausal women, Eur J Clin Invest 1995; 24: 733-736. Go to original source... Go to PubMed...
  21. Writing Group for the Women´s Health Initiative Investigators, JAMA, 2002; July 17, Vol 288 - No 3: 321-333. Go to original source... Go to PubMed...
  22. Živný J. Hormonální substituční terapie. In: Stárka et al. Aktuální endokrinologie. Maxdorf, Praha 1999: 579-588.




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.